Routine supplementary oxygen for the normoxic patient with suspected acute myocardial infarction is no longer warranted. 
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Commentary 
Implications for practice and research 
● In the absence of robust evidence that oxygen is beneficial or harmful, patients with 
suspected acute myocardial infarction (AMI) should have oxygen therapy titrated to 
oxygen saturation levels in accordance with guidelines. 
● A large randomised trial – DET02X-AMI – has recently reported no mortality 
difference at 365 days between normoxic patients with suspected AMI who received 
oxygen vs ambient suggesting supplementary oxygen can safely be withheld in such 
patients.  
 
Context 
Oxygen therapy has been a mainstay of emergency management of patients with suspected 
AMI for decades. In recent years systematic reviews have raised concerns that oxygen may 
be harmful to AMI patients, but the quality of evidence has been low. Following a Cochrane 
review in 2010 international guidelines adopted a more cautious approach to 
recommendations on oxygen than previously, reflecting the lack of evidence. Trials have 
been underpowered, inadequately performed, and failed to answer key questions on 
outcomes of interest to patients. The findings of a ‘definitive’ trial to address the uncertainty 
have recently been reported. 
Methods 
This systematic review was conducted to assess effectiveness and safety of oxygen for 
patients with AMI, and followed guidance from the Cochrane Collaboration and the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Primary 
outcomes were short term mortality and recurrent AMI; secondary outcomes were 
arrhythmia incidence and pain. 
Findings 
Five randomised trials involving 921 patients met inclusion criteria. Risk of bias was unclear 
for one trial and high for the other four. Oxygen administration was not associated with 
reduction in short-term mortality compared with room air (relative risk, RR: 1.08, 95% CI 
0.31-3.74), and there was a significant increase in recurrent AMI in those receiving oxygen 
(RR: 6.73, 95% CI 1.80-25.17). Neither the incidence of arrhythmia or pain were reduced in 
the oxygen group compared to the air group (RR 1.12, 95% CI 0.91-1.36 and RR 0.97, 95% 
CI 0.91-1.04 respectively). 
Commentary 
These findings are broadly consistent with previous Cochrane reviews on this topic. The 
search for the present review overlapped with publication of an updated Cochrane review 
including the same five trials but with a larger population (1173).2 It is assumed that Fu et al. 
only analysed data from trial patients with confirmed AMI. 
None of the included studies managed to answer the question ‘is oxygen helpful or harmful 
in AMI?’ Conducting a robust randomised trial in a sick population such as those with 
suspected AMI, is challenging, with the need to address issues such as how to obtain 
consent,3 how to recruit in the prehospital setting where paramedics may have low exposure 
to patients with the condition of interest, and where the intervention may be administered for 
an hour before the patient reaches hospital (not to forget blinding, and the regulatory 
burden).  Trials focused on ‘hard’ patient outcomes such as mortality need, in AMI, to be 
large and expensive – the risk being that trialists focus on surrogate outcomes such as 
quantification of biomarker release or imaging endpoints.4  
It is possible to design, and secure funding, for robust, adequately powered trials in this 
challenging milieu, and to do so efficiently, reducing cost and burden on participants and 
researchers alike. As this commentary was being drafted, Hofmann and colleagues from 
Sweden reported findings from their registry-based randomised trial in which 6690 patients 
with suspected AMI and had an oxygen saturation > 90% were randomised to 
supplementary oxygen or ambient air and followed up for 365 days. Randomisation and 
follow-up were performed using the Swedish Web-system for Enhancement and 
Development of Evidence-based care in Heart disease Evaluated According to 
Recommended Therapies (SWEDEHEART) registry, linked to administrative datasets. The 
primary end point of death from any cause within 1 year after randomization occurred in 
5.0% of patients (166/3311) assigned to oxygen and in 5.1% of patients (168/3318) 
assigned to ambient air (hazard ratio, 0.97; 95% confidence interval [CI], 0.79 to 1.21; 
P=0.80).1  This landmark trial has immediately influenced international guideline 
recommendations and will change practice worldwide.5 Routine supplementary oxygen for 
the normoxic patient with suspected AMI makes no difference and is no longer warranted. 
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